Prescribing pattern of anti-parkinson drugs in Japan: A trend analysis from 2005 to 2010

Sachiko Nakaoka, Tatsuro Ishizaki, Hisashi Urushihara, Toshihiko Satoh, Shunya Ikeda, Mitsutoshi Yamamoto, Takeo Nakayama

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: Therapeutic options for Parkinson's disease mainly consist of L-dopa and dopamine agonists. However, in Japan, the product labeling of the ergot dopamine agonists, cabergoline and pergolide, was revised in April 2007 due to the risk of developing cardiac valvulopathy. Here, we describe the prescribing trends of anti-Parkinson drugs from 2005 through 2010 in Japan, and examined whether these trends changed after the drug safety measures in 2007. Methods and Patients: We used medical claim data from January 2005 to December 2010 for Parkinson's disease patients older than 30 years who were prescribed anti-Parkinson drugs. We calculated the proportion of patients prescribed each drug for each year, and compared the proportions of first-line drugs prescribed before and after April 2007. We also examined the prescription variations of cabergoline/pergolide users one year before or after April 2007. Results: L-dopa was the most frequently prescribed drug for Parkinson's disease (2005, 58%; 2010, 51%). The proportion of patients prescribed ergot dopamine agonists markedly decreased and non-ergot dopamine agonists increased after 2007. Among first-line drugs, the proportion of non-ergot agents increased after April 2007. Among 54 cabergoline/pergolide users, 24 (44%) discontinued these drugs, nine of whom switched to non-ergot agents. Conclusion: L-dopa was the mainstay of Parkinson's disease treatment between 2005 and 2010 in Japan. There was a decrease in ergot agents and an increase in non-ergot agents prescribed after the regulatory actions in 2007.

Original languageEnglish
Article numbere99021
JournalPLoS One
Volume9
Issue number6
DOIs
Publication statusPublished - 2014 Jun 6

Fingerprint

Japan
drugs
Parkinson disease
Dopamine Agonists
Pergolide
ergot
dopamine
L-dopa
Pharmaceutical Preparations
agonists
Parkinson Disease
Levodopa
Product Labeling
product labeling
Labeling
Prescriptions
Safety
therapeutics
Therapeutics
cabergoline

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Nakaoka, S., Ishizaki, T., Urushihara, H., Satoh, T., Ikeda, S., Yamamoto, M., & Nakayama, T. (2014). Prescribing pattern of anti-parkinson drugs in Japan: A trend analysis from 2005 to 2010. PLoS One, 9(6), [e99021]. https://doi.org/10.1371/journal.pone.0099021

Prescribing pattern of anti-parkinson drugs in Japan : A trend analysis from 2005 to 2010. / Nakaoka, Sachiko; Ishizaki, Tatsuro; Urushihara, Hisashi; Satoh, Toshihiko; Ikeda, Shunya; Yamamoto, Mitsutoshi; Nakayama, Takeo.

In: PLoS One, Vol. 9, No. 6, e99021, 06.06.2014.

Research output: Contribution to journalArticle

Nakaoka, S, Ishizaki, T, Urushihara, H, Satoh, T, Ikeda, S, Yamamoto, M & Nakayama, T 2014, 'Prescribing pattern of anti-parkinson drugs in Japan: A trend analysis from 2005 to 2010', PLoS One, vol. 9, no. 6, e99021. https://doi.org/10.1371/journal.pone.0099021
Nakaoka, Sachiko ; Ishizaki, Tatsuro ; Urushihara, Hisashi ; Satoh, Toshihiko ; Ikeda, Shunya ; Yamamoto, Mitsutoshi ; Nakayama, Takeo. / Prescribing pattern of anti-parkinson drugs in Japan : A trend analysis from 2005 to 2010. In: PLoS One. 2014 ; Vol. 9, No. 6.
@article{f149e2080e3d4e17b107d25a7cbdaf80,
title = "Prescribing pattern of anti-parkinson drugs in Japan: A trend analysis from 2005 to 2010",
abstract = "Objective: Therapeutic options for Parkinson's disease mainly consist of L-dopa and dopamine agonists. However, in Japan, the product labeling of the ergot dopamine agonists, cabergoline and pergolide, was revised in April 2007 due to the risk of developing cardiac valvulopathy. Here, we describe the prescribing trends of anti-Parkinson drugs from 2005 through 2010 in Japan, and examined whether these trends changed after the drug safety measures in 2007. Methods and Patients: We used medical claim data from January 2005 to December 2010 for Parkinson's disease patients older than 30 years who were prescribed anti-Parkinson drugs. We calculated the proportion of patients prescribed each drug for each year, and compared the proportions of first-line drugs prescribed before and after April 2007. We also examined the prescription variations of cabergoline/pergolide users one year before or after April 2007. Results: L-dopa was the most frequently prescribed drug for Parkinson's disease (2005, 58{\%}; 2010, 51{\%}). The proportion of patients prescribed ergot dopamine agonists markedly decreased and non-ergot dopamine agonists increased after 2007. Among first-line drugs, the proportion of non-ergot agents increased after April 2007. Among 54 cabergoline/pergolide users, 24 (44{\%}) discontinued these drugs, nine of whom switched to non-ergot agents. Conclusion: L-dopa was the mainstay of Parkinson's disease treatment between 2005 and 2010 in Japan. There was a decrease in ergot agents and an increase in non-ergot agents prescribed after the regulatory actions in 2007.",
author = "Sachiko Nakaoka and Tatsuro Ishizaki and Hisashi Urushihara and Toshihiko Satoh and Shunya Ikeda and Mitsutoshi Yamamoto and Takeo Nakayama",
year = "2014",
month = "6",
day = "6",
doi = "10.1371/journal.pone.0099021",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Prescribing pattern of anti-parkinson drugs in Japan

T2 - A trend analysis from 2005 to 2010

AU - Nakaoka, Sachiko

AU - Ishizaki, Tatsuro

AU - Urushihara, Hisashi

AU - Satoh, Toshihiko

AU - Ikeda, Shunya

AU - Yamamoto, Mitsutoshi

AU - Nakayama, Takeo

PY - 2014/6/6

Y1 - 2014/6/6

N2 - Objective: Therapeutic options for Parkinson's disease mainly consist of L-dopa and dopamine agonists. However, in Japan, the product labeling of the ergot dopamine agonists, cabergoline and pergolide, was revised in April 2007 due to the risk of developing cardiac valvulopathy. Here, we describe the prescribing trends of anti-Parkinson drugs from 2005 through 2010 in Japan, and examined whether these trends changed after the drug safety measures in 2007. Methods and Patients: We used medical claim data from January 2005 to December 2010 for Parkinson's disease patients older than 30 years who were prescribed anti-Parkinson drugs. We calculated the proportion of patients prescribed each drug for each year, and compared the proportions of first-line drugs prescribed before and after April 2007. We also examined the prescription variations of cabergoline/pergolide users one year before or after April 2007. Results: L-dopa was the most frequently prescribed drug for Parkinson's disease (2005, 58%; 2010, 51%). The proportion of patients prescribed ergot dopamine agonists markedly decreased and non-ergot dopamine agonists increased after 2007. Among first-line drugs, the proportion of non-ergot agents increased after April 2007. Among 54 cabergoline/pergolide users, 24 (44%) discontinued these drugs, nine of whom switched to non-ergot agents. Conclusion: L-dopa was the mainstay of Parkinson's disease treatment between 2005 and 2010 in Japan. There was a decrease in ergot agents and an increase in non-ergot agents prescribed after the regulatory actions in 2007.

AB - Objective: Therapeutic options for Parkinson's disease mainly consist of L-dopa and dopamine agonists. However, in Japan, the product labeling of the ergot dopamine agonists, cabergoline and pergolide, was revised in April 2007 due to the risk of developing cardiac valvulopathy. Here, we describe the prescribing trends of anti-Parkinson drugs from 2005 through 2010 in Japan, and examined whether these trends changed after the drug safety measures in 2007. Methods and Patients: We used medical claim data from January 2005 to December 2010 for Parkinson's disease patients older than 30 years who were prescribed anti-Parkinson drugs. We calculated the proportion of patients prescribed each drug for each year, and compared the proportions of first-line drugs prescribed before and after April 2007. We also examined the prescription variations of cabergoline/pergolide users one year before or after April 2007. Results: L-dopa was the most frequently prescribed drug for Parkinson's disease (2005, 58%; 2010, 51%). The proportion of patients prescribed ergot dopamine agonists markedly decreased and non-ergot dopamine agonists increased after 2007. Among first-line drugs, the proportion of non-ergot agents increased after April 2007. Among 54 cabergoline/pergolide users, 24 (44%) discontinued these drugs, nine of whom switched to non-ergot agents. Conclusion: L-dopa was the mainstay of Parkinson's disease treatment between 2005 and 2010 in Japan. There was a decrease in ergot agents and an increase in non-ergot agents prescribed after the regulatory actions in 2007.

UR - http://www.scopus.com/inward/record.url?scp=84902596923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902596923&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0099021

DO - 10.1371/journal.pone.0099021

M3 - Article

C2 - 24906013

AN - SCOPUS:84902596923

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e99021

ER -